Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative
symbol logo$ANIK Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.25 up 189.29% YoY • Reported revenue of $32.61M up 15.56% YoY • Anika Therapeutics, Inc. is raising its full-year 2026 revenue growth guidance to 5% to 10% and its adjusted EBITDA margin outlook to 13% to 17% for the fiscal year.

Price since post

Full Details

Advertisement|Remove ads.